The short version of tesamorelin fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-22 and is reviewed periodically as new material appears.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
| Property | Value | Notes |
|---|---|---|
| Routine purity assay | Reversed-phase HPLC | Ultraviolet detection near 214 nm |
| Identity confirmation | Liquid chromatography–mass spectrometry | Mass shift reveals modification or truncation |
| Typical purity specification | Greater than 95 percent | Reported as main-peak area percentage |
| Long-term storage | Minus 20 degrees Celsius or colder | Sealed, protected from light |
| Principal degradation routes | Oxidation, deamidation, aggregation | Monitored individually during stability studies |
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
NOS Events – The NOS is also responsible for broadcasting live special events, such as breaking news, weddings of the Dutch royal family, and the Dutch elections. (This department was called NOS Actueel, but that name is defunct since on 1 January 2006 NOS RTV changed its corporate identity) Nieuwsuur (Newshour) – Co-produced with the NTR, the NOS provides news and political affairs coverage for NPO 2's nightly hour-long news magazine programme.
== See also == Sodium hyaluronate, the sodium salt of hyaluronic acid, a glycosaminoglycan found in various human connective tissue. Microbial hyaluronic acid production, the process by which microorganisms are utilized in fermentation to synthesize hyaluronic acid. Alguronic acid, trade name for a mix of polysaccharides produced by microalgae. Inhibits production of hyaluronic-acid-degrading enzymes. Bloomage, a biomaterial company based in China, primarily specialized in hyaluronic acid and other bioactive substance products.
Administration a 100 mg/m2 dose over a one-hour infusion gave a mean total body clearance of 21 L/h/m2 and a mean steady state volume of distribution of 73.8 L/m2 or 123 L based on the mean BSA (body surface area) of 1.68 m2. Area under the plasma concentration-time curve had a mean value of 2.8 mg.h/L. The Cmax of docetaxel was found to be 4.15 ± 1.35 mg/L. Increased dose resulted in a linear increase of the area under the concentration-time curve and so it is concluded that dose is directly proportional to plasma concentration.
John Cox Stevens (1803), founder and first commodore of the New York Yacht Club, won the first America's Cup trophy in 1851 Reginald Sayre (1881), orthopedic surgeon and Olympic sport shooter Charles Sands (1887), athlete who won the gold medal in Golf at the 1900 Summer Olympics Oliver Campbell (1891), tennis player; youngest male winner of the US Open Singles title 1890–1990 Charles Townsend (1893), first Olympic fencer from the Ivy League; silver medalist in the 1904 Summer Olympics Gustavus Town Kirby (1895), president of the United States Olympic Committee 1920–1924, and Amateur Athletic Union 1911–1913 Leo Fishel (1899), first Jewish pitcher in Major League Baseball Harold Weekes (1903), football player for the Columbia Lions, member of the College Football Hall of Fame Harry A. Fisher (1905), basketball coach for Columbia, United States Military Academy, St. John's; member of the Basketball Hall of Fame Robert LeRoy (1905), two-time silver medalist in the 1904 Summer Olympics Eddie Collins (1907), baseball player for the Chicago White Sox and member of the Baseball Hall of Fame Marcus Hurley (1908), cyclist who won four gold medals in Cycling at the 1904 Summer Olympics Jay Gould II* (1911), real tennis player, Olympic gold medalist in 1908 and world champion 1914–1916; great-grandson of financier Jay Gould Ted Kiendl (1911), National Basketball Player of the Year in 1911; corporate lawyer, argued Erie Railroad Co. v.
Sources: en.wikipedia.org
Hypersensitivity to CPA or any of the other components of the medication Pregnancy, lactation, and breastfeeding Puberty (except if being used to treat precocious puberty or delay puberty) Liver diseases and liver dysfunction Chronic kidney disease Dubin–Johnson syndrome and Rotor syndrome History of jaundice or persistent pruritus during pregnancy History of herpes during pregnancy Previous or existing liver tumors (only if not due to metastases from prostate cancer) Previous or existing meningioma, hyperprolactinemia, or prolactinoma Wasting syndromes (except in inoperable prostate cancer) Severe depression Previous or existing thromboembolic processes, as well as stroke and myocardial infarction Severe diabetes with vascular changes Sickle-cell anemia When CPA is used in combination with an estrogen, contraindications for birth control pills should also be considered.
== Stereocenters == Taxifolin has two stereocenters on the C-ring, as opposed to quercetin which has none. For example, (+)-taxifolin has (2R,3R)-configuration, making it one out of four stereoisomers that comprise two pairs of enantiomers.
== Research == Borchers' research centres on the development and application of proteomics and metabolomics technologies, particularly quantitative targeted proteomics for clinical diagnostics. As of July 2026, according to Google Scholar, his publications had been cited more than 33,000 times, with an h-index of 88.
Sources: en.wikipedia.org
=== X-rays === The discovery of X‑rays by Wilhelm Röntgen in 1895 led to widespread experimentation by scientists, physicians, and inventors. Many people began recounting stories of burns, hair loss and worse in technical journals as early as 1896. In February of that year, Professor Daniel and Dr. Dudley of Vanderbilt University performed an experiment involving X-raying Dudley's head that resulted in his hair loss. A report by Dr. H.D. Hawks, of his suffering severe hand and chest burns in an X-ray demonstration, was the first of many other reports in Electrical Review. Other experimenters, including Elihu Thomson and Nikola Tesla, also reported burns. Thomson deliberately exposed a finger to an X-ray tube over a period of time and suffered pain, swelling, and blistering. Other effects, including ultraviolet rays and ozone, were sometimes blamed for the damage, and many physicians still claimed that there were no effects from X-ray exposure at all. Despite this, there were some early systematic hazard investigations, and as early as 1902 William Herbert Rollins wrote almost despairingly that his warnings about the dangers involved in the careless use of X-rays were not being heeded, neither by industry nor by his colleagues. By this time, Rollins had proved that X-rays could kill experimental animals, could cause a pregnant guinea pig to abort, and that they could kill a foetus. He also stressed that "animals vary in susceptibility to the external action of X-light" and warned that these differences be considered when patients were treated by means of X-rays.
However, this occurs mostly in prostate cancer patients who take very high doses of cyproterone acetate; liver toxicity has not been reported in transgender women. Cyproterone acetate also has a variety of other adverse effects, such as fatigue and weight gain, and risks, such as blood clots and benign brain tumors, among others. High dosages of cyproterone-based medication have been linked with meningioma. Periodic monitoring of liver enzymes and prolactin levels may be advisable during cyproterone acetate therapy. Medroxyprogesterone acetate is a progestin that is related to cyproterone acetate and is sometimes used as an alternative to it. It is specifically used as an alternative to cyproterone acetate in the United States, where cyproterone acetate is not approved for medical use and is unavailable. Medroxyprogesterone acetate suppresses testosterone levels in transgender women similarly to cyproterone acetate. Oral medroxyprogesterone acetate has been found to suppress testosterone levels in men by about 30 to 75% across a dosage range of 20 to 100 mg/day. In contrast to cyproterone acetate however, medroxyprogesterone acetate is not also an androgen receptor antagonist. Medroxyprogesterone acetate has similar side effects and risks as cyproterone acetate, but is not associated with liver problems. Numerous other progestogens and by extension antigonadotropins have been used to suppress testosterone levels in men and are likely useful for such purposes in transgender women as well.
== Russian Empire == Each Cossack host consisted of a certain territory with Cossack settlements that had to provide military regiments for service in the Imperial Russian Army and for border patrol operations. Usually the hosts were named after the regions of their location. The stanitsa, or village, formed the primary unit of this organization. In the Russian Empire (1721-1917), the Cossacks constituted twelve separate hosts, settled along the frontiers:
Many substances can influence the P-450 enzyme mechanism. Drugs interact with the enzyme family in several ways. Drugs that modify cytochrome P-450 enzyme are referred to as either inhibitors or inducers. Enzyme inhibitors block the metabolic activity of one or several P-450 enzymes. This effect usually occurs immediately. On the other hand, inducers increase P-450 activity by increasing enzyme production, or, in the case of CYP2E1, preventing degradation in the proteasome. There is usually a delay before enzyme activity increases.
Sources: en.wikipedia.org
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the standard technique for purity and content. Mass spectrometry provides orthogonal confirmation of identity. The two are normally used together rather than in isolation.
Removing water slows hydrolysis and limits the mobility that drives aggregation. A dry powder is also less hospitable to microbial growth. These factors make cold storage of the solid form more forgiving than storage of a reconstituted solution.
Methionine oxidation, asparagine and glutamine deamidation, and non-covalent or covalent aggregation are the main routes reported for peptides of this class. Each is tracked as a separate impurity. Their relative abundance depends on formulation and storage history.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.